Skip to main content
Journal of the Royal Society of Medicine logoLink to Journal of the Royal Society of Medicine
. 1987 Nov;80(11):681–682. doi: 10.1177/014107688708001107

Effects of danazol on mineral homeostasis in normal postmenopausal women: preliminary communication.

D W Purdie 1, A Hay 1, S K Abbas 1
PMCID: PMC1291087  PMID: 3694613

Abstract

The effects of danazol on calcium homeostasis in normal postmenopausal women was examined in a 14-day study utilizing a dosage of 800 mg per day. Danazol caused significant falls in plasma ionized calcium and in the fasting urinary calcium/creatinine ratio, indicating inhibition of bone resorption. Retention of phosphate was also observed as expected with this anabolic agent. The plasma total alkaline phosphatase was also depressed by the drug, which had no effect on hepatocellular function as measured by plasma AST. Certain effects induced by treatment with danazol were still apparent two weeks after cessation of treatment. The drug was well tolerated and androgenic side effects were not seen. It is suggested that the minimal dose regimen of danazol which exerts a calcium-sharing effect should be identified, and that this regimen should be considered for use in a prospective study of the effects of danazol on bone mineral content in the postmenopause.

Full text

PDF
681

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aloia J. F., Kapoor A., Vaswani A., Cohn S. H. Changes in body composition following therapy of osteoporosis with methandrostenolone. Metabolism. 1981 Nov;30(11):1076–1079. doi: 10.1016/0026-0495(81)90050-0. [DOI] [PubMed] [Google Scholar]
  2. Chesnut C. H., 3rd, Ivey J. L., Gruber H. E., Matthews M., Nelp W. B., Sisom K., Baylink D. J. Stanozolol in postmenopausal osteoporosis: therapeutic efficacy and possible mechanisms of action. Metabolism. 1983 Jun;32(6):571–580. doi: 10.1016/0026-0495(83)90027-6. [DOI] [PubMed] [Google Scholar]
  3. Dmowski W. P., Scholer H. F., Mahesh V. B., Greenblatt R. B. Danazol--a synthetic steroid derivative with interesting physiologic properties. Fertil Steril. 1971 Jan;22(1):9–18. doi: 10.1016/s0015-0282(16)37981-x. [DOI] [PubMed] [Google Scholar]
  4. Jick H., Watkins R. N., Hunter J. R., Dinan B. J., Madsen S., Rothman K. J., Walker A. M. Replacement estrogens and endometrial cancer. N Engl J Med. 1979 Feb 1;300(5):218–222. doi: 10.1056/NEJM197902013000502. [DOI] [PubMed] [Google Scholar]
  5. Lindsay R., Hart D. M., Purdie D., Ferguson M. M., Clark A. S., Kraszewski A. Comparative effects of oestrogen and a progestogen on bone loss in postmenopausal women. Clin Sci Mol Med. 1978 Feb;54(2):193–195. doi: 10.1042/cs0540193. [DOI] [PubMed] [Google Scholar]
  6. Selby P. L., Peacock M., Barkworth S. A., Brown W. B., Taylor G. A. Early effects of ethinyloestradiol and norethisterone treatment in post-menopausal women on bone resorption and calcium regulating hormones. Clin Sci (Lond) 1985 Sep;69(3):265–271. doi: 10.1042/cs0690265. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press

RESOURCES